Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- An Aspirational Business Model
- Transformational Drivers
- Paucity of New Products
- Parsimony of Customers
- Pharma' s Aversion to Risk
- R&D Polarization
- Lure and Trap of Patents
- Misreading the Runes
- The Rise of Specialty Pharma
- The Price of Success
- Dealing with Uncertainty
- New Specialty Business Models
- Product Acquisition
- Spin-Offs
- Company Acquisition
- Research & Development
- Specialty Generics
- Drug Delivery and Formulation
- Geographic Specialization
- Therapy Area Specialization
- Customer Specialization
- Unmet Medical Need Specialization
- Orphan Drugs
- Challenges
- Niche-Buster Strategies
- Theranostics
- Value for Money
- The Three Cs: Crowded, Concentrated, and Competitive
- A Specialty Pharma Guide to Success
- Multivectored Business Models
- Lean Structures
- Enhanced Customer Focus
- Real Differentiation
- Value-for-Money
- Greater Acceptance of Risk
- Professionalism
- Capturing the Future
Figures
- 1. Big Pharma, Specialty Pharma, and Biotech-Year-end Market Value, 2006
- 2. Research and Development Expenses, Total NDAs, and NDAs for NME
Submissions, 1993-2004
- 3. Pharma Industry Profi ts from the Developed World, 2006
- 4. Specialty Pharma Forced to Reconfi gure its Business Model
- 5. Specialty Pharma Now Utilizes a Range of Business Models
- 6. Specialty Pharma' s Multivectored Business Models
- 7. Specialty Pharma Needs a Holistic Approach to Differentiation to Create
New Value Perceptions
Tables
- 1. Select Specialty Pharma Companies and Key Drugs-2006 Worldwide Sales
|
Related Report
|
View Cart
